Recently, Xu and collaborators demonstrated that the combination therapy using a Listeria monocytogenes-based tumor vaccine, Lmdd-MPFG, and anti-PD-1 reduced HCC tumor volume and increased survival rates, by inducing CD8 T-cells activation and IFN-γ signals. The gene discussed is CD8A; the disease is hepatocellular carcinoma.